AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oramed Pharmaceuticals Inc.

Major Shareholding Notification Dec 12, 2019

6965_rns_2019-12-12_5de5c8d1-afaf-4347-bd1b-8a3fb3d49aa1.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

SEC Form 3

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
Mayer
Arie
2. Date of Event Requiring
Statement
(Month/Day/Year)
3. Issuer Name and Ticker or Trading Symbol
ORAMED
PHARMACEUTICALS
INC.
[
ORMP ]
(Last)
MORAN 16
(Street)
KFAR SABA L3
(City)
(First)
(State)
(Middle)
4428890
(Zip)
12/05/2019 X 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
Officer (give title
below)
10% Owner
Other (specify
below)
(Month/Day/Year)
Applicable Line)
Reporting Person
5. If Amendment, Date of Original Filed
6. Individual or Joint/Group Filing (Check
X Form filed by One Reporting Person
Form filed by More than One
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities
Beneficially Owned (Instr. 4)
3. Ownership
Form: Direct (D)
or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,000 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)
Expiration Date
(Month/Day/Year)
Date
2. Date Exercisable and 3. Title and Amount of Securities
Underlying Derivative Security (Instr. 4)
4.
Conversion
or Exercise
5.
Ownership
Form:
6. Nature of Indirect
Beneficial Ownership
(Instr. 5)
Exercisable Expiration
Date
Title Price of
Amount
Derivative
or
Security
Number
of
Shares
Direct (D)
or Indirect
(I) (Instr. 5)

Explanation of Responses:

/s/ Arie Mayer 12/11/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Talk to a Data Expert

Have a question? We'll get back to you promptly.